Rational design of indoleamine 2,3-dioxygenase inhibitors.
about
Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaiseSwissDock, a protein-small molecule docking web service based on EADock DSSPsychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behaviorResearch progress of indoleamine 2,3-dioxygenase inhibitorsNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsThe mechanism of formation of N-formylkynurenine by heme dioxygenases.Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenaseCrystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 InhibitorsIn vitro cerebrovascular modeling in the 21st century: current and prospective technologies.Substrate Oxidation by Indoleamine 2,3-Dioxygenase: EVIDENCE FOR A COMMON REACTION MECHANISMIndoleamine 2,3-diooxygenase in periaortic fat: mechanisms of inhibition of contractionIn vitro blood-brain barrier models: current and perspective technologiesDiscovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesSubstituted oxines inhibit endothelial cell proliferation and angiogenesis.3D time-varying simulations of Ca2+ dynamics in arterial coupled cells: A massively parallel implementation.Computational medicinal chemistry in fragment-based drug discovery: what, how and when.Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy.The roles of aryl hydrocarbon receptor in immune responses.The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.Drug repurposing in oncology--patient and health systems opportunities.Major developments in the design of inhibitors along the kynurenine pathway.Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells.Late-Stage C-H Coupling Enables Rapid Identification of HDAC Inhibitors: Synthesis and Evaluation of NCH-31 AnaloguesFused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.The mechanism of substrate inhibition in human indoleamine 2,3-dioxygenase3-Ethenyl-1-(4-methyl-phenyl-sulfon-yl)-1H-indole.Insights into therapy: tryptophan oxidation and HIV infection.Synthesis, molecular and crystal structure analysis of 1-(4-Methylbenzenesulfonyl)indole-3-carbaldehyde and DFT investigation of its rotational conformers.Conformation and tautomerism of methoxy-substituted 4-phenyl-4-thiazoline-2-thiones: a combined crystallographic and ab initio investigation.A New Caged-Glutamine Derivative as a Tool To Control the Assembly of Glutamine-Containing Amyloidogenic Peptides.In Silico and Wet Lab Studies Reveal the Cholesterol Lowering Efficacy of Lauric Acid, a Medium Chain Fat of Coconut Oil.
P2860
Q27001628-FB9BCA88-E595-4503-9D22-85C61D756259Q27144176-0C8EAC30-480E-42D2-8F46-28D3562BE0F9Q27694728-C9A42834-32CA-4AB2-B464-24EEAFC862ECQ28257093-B96BA347-8F30-43AF-A8BA-C9ACECA2C262Q28818166-06DDA359-B666-41E1-B39E-08CC74BAB89FQ34213607-05B24A7B-B6B7-4040-B020-AADFED7F0377Q34252356-8C36D651-BB11-4F53-AD25-5F426C81412FQ34443476-C8D0C6A1-AC55-435E-8143-7AD7B90CD77AQ34476565-A06859A5-BE95-46C9-B343-E801A0518125Q34499772-C2B3889D-3D8F-4F11-A494-1566A5BD7C88Q35395398-D98632AD-DBB4-4BAE-9CE8-B37AC05A87A6Q35782792-7118FB43-7D87-4739-BBB7-61256E6DCB28Q36198024-8D94EE28-78BA-44B7-831E-76F994B8A9DEQ37137360-07827849-FBC7-4C94-AC01-AA03ACB2A879Q37156368-33707F0C-13C9-4F6F-967D-3C3A7E0582FDQ37631964-ECE4A6EB-FCC8-4549-B5C8-30D6759A874DQ37856296-06E341F1-D3E5-4E7C-87C0-296778C7A668Q38061723-6DF04992-0A84-41C1-8DE9-DA732A13136FQ38098490-A5061F6A-8807-42CB-814D-1F2E48D31272Q38103448-F34B9287-7C72-4C44-917B-F5256E64F0C6Q38132933-29DC1184-A72A-4DF2-9040-F6F4473FD587Q38356502-DA5BF2A7-3EBD-411F-BBBD-98B052AFD5A0Q38611707-53B4378E-72B8-417E-A6A4-733C29357DC6Q38808400-275A7580-3FC0-4D09-BA0D-6DCB02887342Q39141333-1DB8EB37-83BE-41E0-949B-38F1FD3676A9Q39785711-4C56ACE9-262D-4D9B-9B39-4B9DB3FA8E61Q40403393-4C917890-DC9D-4401-8207-A02013A73CE8Q40816321-A8B9DC29-E5FE-4A58-9A7F-368EBD7F6489Q41173924-9E8E4A86-C2DD-45DF-8C5B-B154C5EFF234Q42208350-071328B7-AF0D-45E1-9E67-B375205BE9D9Q43059416-424F6288-9D47-4F0A-ABCB-AC53F3736462Q44434940-98BB9ACF-8E7F-499C-A5D5-6170B76E4A42Q46211526-51C55C0A-DD5D-414E-9E09-E66696318129Q50278822-2D0F0BC6-BAC9-48A4-B739-5ED6BAC57538Q51454218-6066095C-CA0A-44F6-9E92-77EA34799999
P2860
Rational design of indoleamine 2,3-dioxygenase inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@ast
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@en
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@nl
type
label
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@ast
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@en
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@nl
prefLabel
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@ast
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@en
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@nl
P2093
P50
P356
P1476
Rational design of indoleamine 2,3-dioxygenase inhibitors.
@en
P2093
Andrew J G Simpson
Benoît J Van den Eynde
Didier Colau
Olivier Michielin
Pierre Larrieu
Pierre Vogel
Ute F Röhrig
Vincent Stroobant
Vincent Zoete
P304
P356
10.1021/JM9014718
P407
P577
2010-02-01T00:00:00Z